The FDA has notified health professionals that Chantix, a smoking cessation product, has been associated with erratic behavior in patients. Some patients reported suicidal thoughts and aggressive behavior within days or weeks of taking Chantix. The FDA is reviewing the cases. For more information about Chantix, view this page.
For more information on this subject, please see our section on Drugs, Medical Devices and Implants.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.